|
FDA Advisory Panel Unanimously Supports Gattex for Short Bowel Syndrome
An FDA advisory panel voted 12–0 Tuesday to recommend approval of NPS Pharmaceuticals’ Gattex as a treatment for short bowel syndrome (SBS).
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives